IsoRay Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | IsoRay Inc.

IsoRay Inc. | Cash Flow

Fiscal year is July-June. All values USD Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

3,856.60

5,959.10

3,681.10

4,710.80

6,162.00

6,700

Depreciation, Depletion & Amortization

770.40

789.90

694.70

666.80

142.00

159

Other Funds

38.70

1,554.10

177.90

241.30

291.00

607

Funds from Operations

3,124.90

3,615.10

3,164.30

4,285.30

5,729.00

5,934

Changes in Working Capital

68.60

386.90

357.50

401.30

17.00

222

Net Operating Cash Flow

3,056.30

3,228.20

3,521.90

3,884.00

5,712.00

5,712

Capital Expenditures

12.70

36.80

151.20

491.80

673.00

Sale of Fixed Assets & Businesses

6.00

Purchase/Sale of Investments

15,404.40

935.00

9,248.70

2,181.00

Net Investing Cash Flow

12.80

15,441.20

783.70

8,757.00

1,514.00

Cash Dividends Paid - Total

10.60

11.00

Net Financing Cash Flow

3,296.30

23,449.50

284.90

39.30

9.00

Net Change in Cash

227.20

4,780.10

2,453.30

4,912.30

4,207.00

Free Cash Flow

3,062.80

3,247.30

3,655.20

4,363.20

6,261.00

Change in Capital Stock

3,306.90

23,460.20

295.50

49.90

2.00

Other Uses

0.10

About IsoRay

View Profile

Address	350 Hills Street Richland Washington 99354 United States
Employees	-
Website	http://www.isoray.com
Updated	07/08/2019
IsoRay, Inc. is a medical technology company. Though its subsidiary IsoRay Medical, Inc., it develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Its product include Cesium-131 (Cs-131), a radioisotope for the treatment of prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma, and pancreatic cancer.